Allscripts (MDRX) Misses Q4 EPS by 1c, Offers Guidnce
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Jefferies Reiterates Buy on Allscripts (MDRX) Following 4Q
February 17, 2017 8:26 AM ESTJefferies reiterated a Buy rating and $16.50 price target on Allscripts (NASDAQ: MDRX) following 4Q earnings report. MDRX reported EPS of $0.14, which compares to $0.15 for consensus. Downside was driven by higher SG&A, partially offset by better revenue, a higher gross margin and... More
Allscripts (MDRX) PT Raised to $13 at Cantor Fitzgerald Following In-Line 4Q Results
February 17, 2017 7:22 AM ESTCantor Fitzgerald analyst Steven Halper reiterates Neutral rating and raises price target on Allscripts Healthcare Solutions Inc. (NASDAQ: MDRX) to $13 (from $12), suggesting shares remain fairly valued, as the company reported 2016 fourth quarter results in-line with estimates, while 2017 guidance was also in-line with... More
